Mycobacterium avium complex infection in the acquired immunodeficiency syndrome
about
Diagnosis and Treatment of Disease Caused by Nontuberculous MycobacteriaLaboratory aspects of "Mycobacterium genavense," a proposed species isolated from AIDS patientsFrequency of tuberculous and non-tuberculous mycobacteria in HIV infected patients from Bogota, ColombiaGenomic homogeneity between Mycobacterium avium subsp. avium and Mycobacterium avium subsp. paratuberculosis belies their divergent growth ratesUtilization of a ts-sacB selection system for the generation of a Mycobacterium avium serovar-8 specific glycopeptidolipid allelic exchange mutantGeneral Overview on Nontuberculous Mycobacteria, Biofilms, and Human Infection'"Why me, why now?" Using clinical immunology and epidemiology to explain who gets nontuberculous mycobacterial infectionIncidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study GroupActivities of WIN-57273, minocycline, clarithromycin, and 14-hydroxy-clarithromycin against Mycobacterium avium complex in human macrophagesIn vitro activities of clarithromycin and azithromycin against clinical isolates of Mycobacterium avium-M. intracellulareMefloquine is active in vitro and in vivo against Mycobacterium avium complexActivity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium aviumClarithromycin, dapsone, and a combination of both used to treat or prevent disseminated Mycobacterium avium infection in beige miceIn vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859aActivity of KRM 1648 alone or in combination with ethambutol or clarithromycin against Mycobacterium avium in beige mouse model of disseminated infectionRifabutin and sparfloxacin but not azithromycin inhibit binding of Mycobacterium avium complex to HT-29 intestinal mucosal cellsComparative in vivo activities of rifabutin and rifapentine against Mycobacterium avium complexRifabutin is active in murine models of toxoplasmosisAzithromycin, rifabutin, and rifapentine for treatment and prophylaxis of Mycobacterium avium complex in rats treated with cyclosporineActivities of fluoroquinolone, macrolide, and aminoglycoside drugs combined with inhibitors of glycosylation and fatty acid and peptide biosynthesis against Mycobacterium aviumIn vitro antimycobacterial activities of pyrazinamide analogsSusceptibility testing of Mycobacterium avium complex isolatesEnhanced intramacrophage activity of resorcinomycin A against Mycobacterium avium-Mycobacterium intracellulare complex after liposome encapsulationTreatment of intracellular Mycobacterium avium complex infection by free and liposome-encapsulated sparfloxacinEmergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy.Identification of a heparin-binding hemagglutinin present in mycobacteriaMolecular characterization of the mycobacterial heparin-binding hemagglutinin, a mycobacterial adhesinDetection of natural infection with Mycobacterium intracellulare in healthy wild-caught Chacma baboons (Papio ursinus) by ESAT-6 and CFP-10 IFN-gamma ELISPOT tests following a tuberculosis outbreakElevated tumor necrosis factor-alpha in association with severe anemia in human immunodeficiency virus infection and Mycobacterium avium intracellulare infection.The pathophysiology of disseminated Mycobacterium avium complex disease in AIDS.Dual color fluorescence in situ hybridization (FISH) assays for detecting Mycobacterium tuberculosis and Mycobacterium avium complexes and related pathogens in cultures.Medical and virological aspects of ocular human immunodeficiency virus infection for the ophthalmologist.Heme oxygenase-1 promotes granuloma development and protects against dissemination of mycobacteria.Infection with Mycobacterium avium induces production of interleukin-10 (IL-10), and administration of anti-IL-10 antibody is associated with enhanced resistance to infection in mice.Microbiological safety of drinking water: United States and global perspectives.Emergence of a unique group of necrotizing mycobacterial diseases.Temporal variations in the abundance and composition of biofilm communities colonizing drinking water distribution pipes.Fatal pulmonary infection with Mycobacterium celatum in an apparently immunocompetent patient.Routine use of PCR-reverse cross-blot hybridization assay for rapid identification of Mycobacterium species growing in liquid media.Sparfloxacin, ethambutol, and cortisol receptor inhibitor RU-40 555 treatment for disseminated Mycobacterium avium complex infection of normal C57BL/6 mice.
P2860
Q22241907-7470E3B6-B2E6-4974-BCBF-BD18E7E9F39CQ24652409-2A3B777C-1CFB-4660-A6C3-9070454B5135Q24795304-AF2A2240-6B60-4222-B420-E0C0C4F26E19Q24801171-7F76FC5E-75E5-4BE8-ACA5-2FABAF855F08Q24803824-910A2174-07EF-4605-AA8D-F25252B15611Q26776061-099B6EC2-E1B1-405F-B93B-A874BB40DE2BQ28070339-E197841B-28E6-41D9-9B73-33C3C6AFE22BQ28184540-B6D21C70-F9E9-415F-BE79-B34E40B6F4FEQ28326992-B023EEF8-D066-412F-963B-A1EDC3F92512Q28343406-91B5E774-E521-4E21-8138-F9341E0BD595Q28343464-908B9064-AC28-40A2-80D6-F12746D41E4EQ28345248-6DEFE185-BB36-4BC9-9F5F-B4201D530C34Q28368056-33E4A1CD-4FA9-4FA0-92D0-2FD3B66EBFDFQ28368060-34614D4F-0208-4BFF-A124-F8B6FA5BCD41Q28369155-D682BBAC-A612-4DFF-9E1F-8A4214230A42Q28369391-6149FBF9-188B-4145-8F26-5DB771CCA4A4Q28369712-9E41B240-7333-42EE-B109-71B0B4E12399Q28378281-F3C25ACD-6EF0-4A22-BA7E-14C712698D08Q28378617-3F29F3C6-20C1-40AC-8899-D8F9E9C1AFF6Q28378705-2025E1D6-24C2-4F85-8B86-F9246B331636Q28378748-C5FCCC4D-D260-4806-ADD2-06C0DDE7A323Q28379189-910EE58B-79BF-4B44-A4FB-2395204D024FQ28379296-AFA1E78E-A44E-4A6A-A8B3-F8B9F7CE9233Q28379298-60FEE12E-DEA9-4324-AD3E-282714CD817AQ28379322-35A4DC08-00B3-450A-A2F3-BF19F286A720Q28486374-3D181E38-3327-4045-8605-A441403237E4Q28486660-BF6E2014-8E69-4D46-A9CA-AEFC92A945ADQ33318591-E9829BA4-9941-4EB6-93A3-8FB247FFBCEBQ33488909-5A21B79E-BA3D-457A-ACFC-DB6C7619DE53Q33547154-C9985412-43E5-4BED-AF5A-F7853ECBEE8FQ33553943-93F40386-B76C-4A95-835B-B57D895DF403Q33569593-50D7B3FF-B28F-4351-BE8E-A0E07BE8EFBDQ33596050-EF36FB26-CAA0-4D6E-9CAB-8A0C081568F9Q33603597-F540C780-4FC7-4A86-9484-3BECF69A74B8Q33608828-16D44993-F1E0-4E93-BCF9-E69C034E9E9BQ33643091-660A0C0E-499C-4DFB-932B-38E4C2B12EA5Q33655215-C4BF3FDC-AC91-4C65-93B9-B1240A2505F0Q33657863-434CF089-23C0-456C-AAC5-E88F473EFF20Q33668698-72BFB115-CC02-4E91-B986-22AE38F9EFC2Q33745057-20B2E19D-2F46-48F6-A97B-31158D7A807E
P2860
Mycobacterium avium complex infection in the acquired immunodeficiency syndrome
description
1991 nî lūn-bûn
@nan
1991 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Mycobacterium avium complex infection in the acquired immunodeficiency syndrome
@ast
Mycobacterium avium complex infection in the acquired immunodeficiency syndrome
@en
Mycobacterium avium complex infection in the acquired immunodeficiency syndrome
@nl
type
label
Mycobacterium avium complex infection in the acquired immunodeficiency syndrome
@ast
Mycobacterium avium complex infection in the acquired immunodeficiency syndrome
@en
Mycobacterium avium complex infection in the acquired immunodeficiency syndrome
@nl
prefLabel
Mycobacterium avium complex infection in the acquired immunodeficiency syndrome
@ast
Mycobacterium avium complex infection in the acquired immunodeficiency syndrome
@en
Mycobacterium avium complex infection in the acquired immunodeficiency syndrome
@nl
P3181
P1476
Mycobacterium avium complex infection in the acquired immunodeficiency syndrome
@en
P2093
C R Horsburgh
P304
P3181
P356
10.1056/NEJM199105093241906
P407
P577
1991-05-09T00:00:00Z